🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

47 results for “Beijing” Clear

  1. Sibeprenlimab, Sibeprenlimab placebo

    Otsuka Beijing Research Institute

    Treatment of Sjögren’s disease

    phase 2 small molecule active

    1 trial

  2. TwHF

    Beijing 302 Hospital

    Human Immunodeficiency Virus

    phase 2 small molecule active

    1 trial

  3. 100 mg Delamanid

    Otsuka Beijing Research Institute

    Multidrug Resistant Tuberculosis

    phase 1 small molecule completed

    1 trial

  4. A Trial to Determine if Quabodepistat is Processed Differently in Adults with Reduced Liver Function Compared to Adults with Normal Liver Function

    Otsuka Beijing Research Institute

    Tuberculosis

    phase 1 other active

    1 trial

  5. A Trial to Examine the Effects of MSP-2020 on Brain Activity in Healthy Adults

    Otsuka Beijing Research Institute

    Incomplete Response - Major Depressive Disorder (IR-MDD)

    phase 1 other active

    1 trial

  6. A phase 1 trial to evaluate the safety, tolerability, pharmacodynamics, pharmacokinetics, and immunogenicity of VIS171 in participants with autoimmune disease(s)

    Otsuka Beijing Research Institute

    Systemic lupus erythematosus, Immune-mediated focal segmental glomerulosclerosis, Alopecia Areata

    phase 1 other active

    1 trial

  7. BioTTT001 injection

    Beijing Zhifei Lvzhu Biopharmaceutical Co., Ltd

    Locally Advanced Breast Cancer (LABC)

    phase 1 mab terminated

    1 trial

  8. OPB-31121

    Otsuka Beijing Research Institute

    Non-Hodgkin's Lymphoma(NHL)

    phase 1 small molecule completed

    1 trial

  9. OPC-108459

    Otsuka Beijing Research Institute

    Atrial Fibrillation

    phase 1 small molecule completed

    1 trial

  10. Tolvaptan 15mg or 30mg or 60mg or Placebo

    Otsuka Beijing Research Institute

    Healthy

    phase 1 small molecule completed

    1 trial

  11. Vagus Nerve Stimulation

    Beijing Zhifei Lvzhu Biopharmaceutical Co., Ltd

    Refractory Epilepsy

    phase 1 other active

    1 trial

  12. YN001

    Beijing Zhifei Lvzhu Biopharmaceutical Co., Ltd

    Cardiovascular Diseases

    phase 1 small molecule completed

    1 trial

  13. Aripiprazole

    Otsuka Beijing Research Institute

    Schizophrenia

    approved small molecule completed

    3 trials

  14. Cilostazol

    Otsuka Beijing Research Institute

    Polyneuropathy

    approved small molecule completed

    1 trial

  15. Cilostazol

    Otsuka Beijing Research Institute

    Cerebral Infarction

    approved small molecule completed

    1 trial

  16. Procaterol

    Otsuka Beijing Research Institute

    Asthma

    approved small molecule completed

    1 trial

  17. Rebamipide

    Otsuka Beijing Research Institute

    Stomach Ulcer

    approved small molecule completed

    1 trial

  18. Tolvaptan

    Otsuka Beijing Research Institute

    Hyponatremia and Extracellular Fluid in Cirrhotic

    approved small molecule terminated

    1 trial

  19. aripiprazole

    Otsuka Beijing Research Institute

    Bipolar Disorder

    approved small molecule completed

    1 trial

  20. CYP2C19 genotype testing

    Beijing Anzhen Hospital

    Angina, Stable

    gene therapy active

    1 trial

  21. Corticosteroid

    Beijing Anzhen Hospital

    Heart Valve Diseases

    small molecule completed

    1 trial

  22. caspofungin

    Beijing Chao Yang Hospital

    Pneumocystis Pneumonia

    small molecule active

    1 trial

  23. evolocumab

    Beijing Luhe Hospital

    STEMI

    small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources